AML Drug Moves Into Clinical Trials Following FDA Clearance
The first patient has now been dosed with AMX-883 for acute myeloid leukemia.
Each day, hundreds of billions of new cells are produced in the bone marrow; each type is essential for a different reason.
Red blood cells carry oxygen to tissues for energy, white blood cells are key in the immune response, and platelets help maintain blood hemostasis (the balance between bleeding and clotting).
Despite having different physiological roles, each of these cells differentiates from the same type of immature myeloid precursor cell, or blast, found in the bone marrow. Abnormalities in these cells and their differentiation can lead to a range of complications, each linked to specific cellular functions: anemia and fatigue, bleeding disorders, and increased risk of infection, among many more.
These complications may be the first sign of acute myeloid leukemia (AML), a rare cancer affecting myeloid precursor cells. Although AML is a rare disease, the burden is far from small. There are estimated to be over 22,000 new AML cases and more than 11,000 related deaths in the United States this year alone.
Behind each case is an individual who must decide between the treatment regimens offered to them: intensive chemotherapy, radiotherapy, cell transplants, or newer medicines that depend on the presence of specific mutations and carry the risk of drug resistance.
Bromodomain-containing protein 9 (BRD9) has emerged as a compelling therapeutic target for AML. Technology Networks spoke with Dr. Louise Modis, chief executive officer at Amphista, to find out why this is the case.
Modis shared insights into the development of AMX-883, Amphista’s lead Targeted Glue™ degrader of BRD9, discussed the advantages of the mutation-agnostic approach, and highlighted translational considerations as the therapy moves toward Phase 1 studies—the first patient has now been dosed.
Why was BRD9 considered a therapeutic target for AML?
AML is an aggressive blood cancer maintained by a block in myeloid cell differentiation, typically exhibiting rapid disease progression and poor prognosis. Historically, cytotoxic chemotherapy, stem cell transplants, and targeted small-molecule inhibitors have been used to treat patients with AML. However, success has been limited, with significant variability in patient responses as well as therapy-related toxicities and acquired drug resistance.
Recently, BRD9 has emerged as a key node in the pathogenesis of AML. BRD9 acts as a comprehensive regulator of myeloid gene expression, activating survival pathways and maintaining the self-renewing, progenitor state in leukemic blasts. Leukemic cells heavily dependent on BRD9 and its expression is elevated in all forms of AML. Degrading, not inhibiting, BRD9 blocked patient-derived tumor growth in vivo, making it an attractive target for novel, broad-acting pro-differentiation therapies in AML.
There has been significant progress in novel targeted treatments for AML over recent years. However, these approaches are mutation-specific and, therefore, only target a small subset of AML patients. In addition, patients may require genetic tests to confirm the presence of certain mutations within their tumor before treatment can be given.
“Novel therapeutics capable of inducing differentiation across a broader range of AML, without the need to wait for prior genetic testing, remain a central unmet need in AML.” — Dr. Louise Modis.
TPD exploits a cell’s ubiquitin-proteasome system (UPS) to selectively eliminate proteins, rather than simply inhibiting their activity. To date, proteolysis-targeting chimeras (PROTACs) and molecular glues are the most commonly explored TPD therapeutics. However, each approach presents distinct challenges, including the large size and complex structure of PROTACs, and the potential for off-target effects in both modalities.
Understanding PROTACs and molecular glues
In the degradation of unwanted proteins via the UPS, an E3 ligase binds the target protein. Ubiquitin is transferred to the target protein via an E2 carrier protein, which is also bound by the E3 ligase. The ubiquitin marks the target protein for degradation.
- PROTACs are chemical compounds with two distinct functional ends connected by a linker. In TPD, each end of the PROTAC binds either the target protein or an E3 ligase, bringing them into proximity and triggering degradation processes.
- Molecular glues are small molecules that induce protein–protein interactions. In TPD, they bind either the target protein or E3 ligase, helping trigger targeted degradation.
We have developed Targeted Glues which combine the bifunctionality of PROTACs with the small molecule design of molecular glues to produce a highly selective therapy with chemical properties optimized for human medicines. By removing the entire protein, as opposed to inhibiting a singular domain, TPD could drive deeper anti-tumor responses and efficacy.
“Another benefit of TPD is that it expands the druggable space to include targets with functions not linked to enzyme activity, such as BRD9, potentially opening avenues to entirely new medicines for patients.” — Dr. Louise Modis.
The initial design of AMX-883 was based on the identified target product profile (TPP): a potent, selective, orally available BRD9 degrader, with a favorable safety profile. With BRD9 as the selected target, we built and tested a modular degrader library combining known BRD9 binders, linkers, and electrophilic warheads designed for E3 ligase engagement.
Binders, linkers, and warheads in TPD
In TPD, the “warhead” binds to the target protein, the binder attaches to the E3 ligase, and the linker connects the two.
The tool compound AMPTX-1 emerged from this screening campaign as a potent BRD9 degrader. Critically, the degradation activity of this compound is dependent on the formation of a reversible-covalent BRD9-bound complex before the Targeted Glue can recruit DCAF16 [which tags target proteins with ubiquitin for degradation].
The optimization of AMPTX-1 to produce AMX-883 focused on increasing the speed of degradation, which is crucial for in vivo efficacy, while maintaining selectivity and improving pharmacokinetics. This was achieved by altering the structures of both the linker and warhead, which reduced degradation time from six hours to two hours and resulted in an orally bioavailable clinical candidate with sub-nanomolar potency and selectivity over related bromodomain proteins.
Another important consideration was the cardiovascular toxicities that have been seen in cereblon (CRBN)-recruiting-based degraders. By using a DCAF16-mediated approach, we hope to avoid such issues. We performed extensive in vitro and in vivo preclinical testing to derisk our chemistry, with no evidence of cardiovascular changes observed.
CRBN-recruiting-based vs DCAF16-mediated degradation
CRBN and DCAF16 are both substrate receptors of E3 ligases. Compounds that bind CRBN, including thalidomide, have been reported to alter the receptor surface, resulting in the degradation of proteins beyond the intended target. BRD9 binds the DCAF16 receptor, but this is dependent on binding AMX-883 first, which is expected to provide an additional layer of selectivity.
Typical challenges that arise during Phase 1 clinical trials include questions of exposure and safety. The pharmacokinetics and tolerability of AMX-883 will be strictly monitored to assess pharmacodynamics, side effects, and maximum safe doses.
Another challenge that we will face is that patients with AML are often critically ill and highly vulnerable, especially those whose disease harbors the TP53 mutation, which is associated with poor patient outcomes. Additionally, inherent characteristics of AML such as rapid disease progression and profound immunosuppression could also impact patient enrolment, treatment delivery, and could ultimately result in a lower degree of efficacy.
However, the ability to identify differentiation in cells, combined with our team’s extensive experience, will ensure that we recognize early signs of efficacy.
What potential does targeted protein degradation hold across other indications, particularly those within your pipeline?
By enabling the recruitment of novel E3 ligases beyond traditional avenues, we are expanding the druggable space, increasing degradation selectivity, and unlocking new degradation mechanisms.
“Our novel chemistry is enabling the development of more potent, selective drugs for established targets, leading to greater efficacy for patients.” — Dr. Louise Modis.
Within our pipeline, we have Targeted Glues designed to treat non-small cell lung cancer. Earlier programs in development will expand the scope of Targeted Glues into neurodegenerative diseases.